A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis

July 3, 2026 updated by: Ono Pharmaceutical Co., Ltd.

A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Hunner Type Interstitial Cystitis

To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Hunner Type Interstitial Cystitis

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
57

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Japan
      • Nagasaki, Japan
        • Nagasaki University Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan
        • Nagoya University Hospital
    • Fukuoka
      • Fukuoka, Fukuoka, Japan
        • Harasanshin Hospital
    • Fukushima
      • Fukushima, Fukushima, Japan
        • Fukushima Medical University Hospital
    • Gifu
      • Gifu, Gifu, Japan
        • Japanese Red Cross Gifu Hospital
    • Gunma
      • Takasaki, Gunma, Japan
        • Kurosawa Hospital Health Park Clinic
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Japan
        • Niimura Hospital
    • Kanagawa
      • Kawasaki, Kanagawa, Japan
        • Kanto Rosai Hospital
    • Kyoto
      • Kyoto, Kyoto, Japan
        • Rakuwakai Marutamachi Hospital
      • Kyoto, Kyoto, Japan
        • Ueda Clinic
    • Miyagi
      • Sendai, Miyagi, Japan
        • Izumi Chuo Hospital
    • Nagano
      • Matsumoto, Nagano, Japan
        • Shinshu University Hospital
    • Oita Prefecture
      • Beppu, Oita Prefecture, Japan
        • Nakamura Hospital
    • Okayama-ken
      • Okayama, Okayama-ken, Japan
        • Okayama University Hospital
    • Saga-ken
      • Saga, Saga-ken, Japan
        • Nanri Urological Clinic
    • Tokyo
      • Minato-Ku, Tokyo, Japan
        • The Jikei University Hospital
      • Mitaka, Tokyo, Japan
        • Kyorin University Hospital
      • Tokyo, Tokyo, Japan
        • The University of Tokyo Hospital
    • Toyama
      • Uozu, Toyama, Japan
        • Toyama Rosai Hospital
    • Yamanashi
      • Chūō, Yamanashi, Japan
        • University of Yamanashi Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Japanese (both sexes)
  • Age (at the time of informed consent): 18 years and older
  • Outpatient
  • Patients who are considered capable of understanding the study procedures and completing the pain diary, bladder diary, and questionnaires appropriately by the investigator (sub-investigator）
  • Patients given a diagnosis of HIC by cystoscopy
  • Patients with chronic pelvic pain involving the bladder and lower urinary tract symptoms such as increased micturition and pollakiuria

Exclusion Criteria:

  • Patients with a history and presence of chemical cystitis
  • Patients with a history of bladder augmentation or radical cystectomy
  • Patients with pain other than HIC that may affect assessments in this study
  • Patients with a past history of or concurrent neurologic diseases that may affect assessments in this study
  • Patients receiving medications for psychiatric disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: Placebo
Placebo tablets once daily
Drug: Placebo
Placebo tablets once daily
Experimental: ONO-1110
ONO-1110 tablets once a day
Drug: ONO-1110
ONO-1110 tablets once a day

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Change in weekly mean of average pain score from baseline to Week 12 of the treatment period
Time Frame: Up to 20 weeks
Up to 20 weeks
Adverse events
Time Frame: Up to 20 weeks
Up to 20 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in weekly mean of average pain score from baseline in each week
Time Frame: Up to 20 weeks
Up to 20 weeks
30%- and 50%-responder rates based on the weekly mean of average pain score
Time Frame: Up to 20 weeks
proportions of participants whose weekly mean of average pain score has decreased by 30% and 50% from baseline, respectively
Up to 20 weeks
Change in weekly mean of worst pain score from baseline to each week
Time Frame: Up to 20 weeks
Up to 20 weeks
30%- and 50%-responder rates based on the weekly mean of worst pain score
Time Frame: Up to 20 weeks
proportions of participants whose weekly mean of worst pain score has decreased by 30% and 50% from baseline, respectively
Up to 20 weeks
Change in Interstitial cystitis symptom index (ICSI) score from baseline
Time Frame: Up to 20 weeks
Up to 20 weeks
Change in Interstitial cystitis problem index (ICPI) score from baseline
Time Frame: Up to 20 weeks
Up to 20 weeks
Change in Average frequency of urination per day from baseline
Time Frame: Up to 20 weeks
Up to 20 weeks
Change in Frequency of nocturnal urination per day from baseline
Time Frame: Up to 20 weeks
Up to 20 weeks
Change in Mean volume voided per micturition in a day from baseline
Time Frame: Up to 20 weeks
Up to 20 weeks
Change in Maximum volume voided per micturition in a day from baseline
Time Frame: Up to 20 weeks
Up to 20 weeks
Change in Number of urgency episodes per day from baseline
Time Frame: Up to 20 weeks
Up to 20 weeks
Change in Patient Global Impression of Change (PGIC) score from baseline
Time Frame: Up to 20 weeks
Up to 20 weeks
Change in SF-12v2 score from baseline
Time Frame: Up to 20 weeks
Up to 20 weeks
Change in Hospital Anxiety and Depression Scale (HADS) score from baseline
Time Frame: Up to 20 weeks
Up to 20 weeks
Plasma ONO-1110 concentrations
Time Frame: Up to 20 weeks
Up to 20 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ono Pharmaceutical Co., Ltd.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Project Leader, Ono Pharmaceutical Co., Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 2, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 12, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 12, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 22, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 22, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 30, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 7, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 3, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • ONO-1110-06
  • jRCT2031240558 (Registry Identifier: Japan Registry of Clinical Trials)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings